176 related articles for article (PubMed ID: 7702012)
21. [Effect of human recombinant-gamma interferon on the immune function of peripheral blood lymphocytes in cancer patients].
Yamada J; Tanaka N; Kamitani S; Goto K; Gangi J; Orita K
Gan To Kagaku Ryoho; 1986 May; 13(5):1946-52. PubMed ID: 2939802
[TBL] [Abstract][Full Text] [Related]
22. [Clinical effects and immunological changes in interferon therapy for advanced renal cell carcinoma].
Kudo T; Souma H; Kudo S; Kogawa T; Suzuki T
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):40-6. PubMed ID: 2109026
[TBL] [Abstract][Full Text] [Related]
23. Immunologic monitoring studies in advanced cancer patients treated with recombinant human gamma interferon (IFN-gamma 4A).
Romano PJ; Lipton A; Harvey HA; Bartholomew MJ; Giudice G; Kloszewski F; Witkowski L; Downing MR
Mol Biother; 1989; 1(4):208-12. PubMed ID: 2510768
[TBL] [Abstract][Full Text] [Related]
24. T-lymphocyte subsets in the peripheral blood of patients with renal cell carcinoma.
Mitropoulos D; Alamanis C; Deliveliotis C; Zervas A; Tzirakis A; Dimopoulos C
Acta Urol Belg; 1995 Sep; 63(3):21-5. PubMed ID: 7484518
[TBL] [Abstract][Full Text] [Related]
25. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
26. [Multidisciplinary therapy using interferon and immunological evaluation for glioma patients: two-color analysis of T cell subsets].
Numa Y; Kawamoto K; Matsumura H
No Shinkei Geka; 1991 Feb; 19(2):121-8. PubMed ID: 1708857
[TBL] [Abstract][Full Text] [Related]
27. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
28. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
29. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines.
Szodoray P; Gal I; Barath S; Aleksza M; Horvath IF; Gergely P; Szegedi G; Nakken B; Zeher M
Scand J Rheumatol; 2008; 37(3):205-12. PubMed ID: 18465456
[TBL] [Abstract][Full Text] [Related]
30. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
31. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
32. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
33. [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer].
Cui M; Wang S; Ye YJ; Cui ZR; Ke Y
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(1):16-9. PubMed ID: 17403305
[TBL] [Abstract][Full Text] [Related]
34. Natural killer, natural killer T, helper and cytotoxic T cells in the decidua from sporadic miscarriage.
Shimada S; Nishida R; Takeda M; Iwabuchi K; Kishi R; Onoé K; Minakami H; Yamada H
Am J Reprod Immunol; 2006 Sep; 56(3):193-200. PubMed ID: 16911715
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
36. The antitumor effects of IFN- beta against human renal cell carcinoma in athymic nude mice.
Shirahama T; Kayajima T; Ohi Y
In Vivo; 1989; 3(5):345-9. PubMed ID: 2519876
[TBL] [Abstract][Full Text] [Related]
37. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
[TBL] [Abstract][Full Text] [Related]
38. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
40. Cyclic interferon gamma application in patients with renal cell carcinoma.
Grups JW; Frohmüller HG
Prog Clin Biol Res; 1990; 350():257-62. PubMed ID: 2117285
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
